{
    "id": "0674",
    "question": "An experimental new drug in the treatment of diabetes mellitus type 2 was found to increase the levels of incretins by preventing their degradation at the endothelium. This further increased glucose-dependent insulin production. Which of the following drugs has a mechanism of action most similar to this new experimental drug?",
    "options": {
        "A": "Sitagliptin",
        "B": "Glimepiride",
        "C": "Canagliflozin",
        "D": "Pioglitazone"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To solve this question, we need to understand the mechanism of action of each mentioned drug and compare it to the new experimental drug. The new experimental drug increases glucose-dependent insulin production by preventing the degradation of incretins at the endothelium. Incretins are hormones that stimulate insulin release in response to high blood glucose levels. Sitagliptin (A) is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases incretin levels by blocking the enzyme that breaks down incretins. However, it does not prevent the degradation of incretins at the endothelium. Glimepiride (B) is a sulfonylurea, which stimulates insulin release from the pancreas by binding to a receptor on the surface of pancreatic beta cells. Its mechanism of action does not involve incretins or endothelial protection. Canagliflozin (C) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor, which increases glucose excretion in the urine and reduces blood glucose levels. It does not affect incretin levels or their degradation at the endothelium. Pioglitazone (D) is a thiazolidinedione, which increases insulin sensitivity in peripheral tissues by activating peroxisome proliferator-activated receptor-gamma (PPAR-\u03b3). Its mechanism of action does not involve incretins or endothelial protection. Considering the given information, none of the mentioned drugs have a mechanism of action that exactly matches the new experimental drug. However, the closest match would be Sitagliptin (A), as it also increases incretin levels by blocking their degradation, albeit at a different site (the bloodstream).\", \"answer_choice\": \"A\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 64.35781025886536
}